Application of Ectoin Allergy Nasal Spray in Comparison to Beclomethasone Nasal Spray
Launched by BITOP AG · May 6, 2014
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed allergic rhinitis during the observational period
- Exclusion Criteria:
- • Contra indications according to the label
About Bitop Ag
Bitop AG is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions for dermatological and infectious diseases. With a commitment to advancing healthcare through cutting-edge research, Bitop AG specializes in the formulation of novel compounds and the optimization of existing treatments. The company leverages its expertise in pharmacology and biotechnology to conduct rigorous clinical trials, ensuring safety and efficacy while addressing unmet medical needs. Bitop AG is dedicated to improving patient outcomes and enhancing therapeutic options through its collaborative approach and state-of-the-art technology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Uwe Sonnemann, MD
Principal Investigator
HNO Praxis Elmshorn
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials